←
Kyle G Daniels1,198 posts
Kyle G Daniels avatar✓

Kyle G Daniels ✓

@ScienceKyle

Assistant Professor @Stanford University Genetics. Synthetic Biologist // Real Human 🧬 🔬 💻 🏳️‍🌈 🏊🏾‍♂️

◷ Joined January 2022▧ 43 Photos and videos
Kyle G Daniels avatar
Kyle G Daniels@ScienceKyle·May 14

🚨What if we could reliably program macrophage polarization state?🚨 biorxiv.org/content/10.64898… Macrophages are highly plastic immune cells that perform critical functions by polarizing into distinct cellular states. The polarization state of macrophages can substantially influences the progression of cancers, infections, and autoimmunity. (1/11)

Post attachment
Brian Hie avatar
⟳ Kyle G Daniels retweeted
Brian Hie@BrianHie·20h

In new work, we lay out a vision for therapeutic design that can "see into the future." We first introduce a method for state-of-the-art prediction of viral evolution. We then develop a framework for de novo antibody design against multiple targets from cancer and viral diseases. Excitingly, we then put these together to design antibodies with potent pseudoviral neutralization against both current and forecasted escape variants. This lays the groundwork for more evolutionarily resilient therapeutic design, as well as better tools for public health, pandemic preparedness, and biodefense. Predicting evolution: biorxiv.org/content/10.64898… Responding to and anticipating evolution: biorxiv.org/content/10.64898…

Post attachment
Hani Goodarzi avatar
⟳ Kyle G Daniels retweeted
Hani Goodarzi@genophoria·Nov 16

Congratulations @seresanu and team, including Shaopu in our lab. Amazing to see this out… Serena and I first discussed this at a @biohub investigator lunch many years ago! It turns out asking grantees to show up to most weekly meetings works as intended!

Post attachment
Delgoffe Lab avatar
⟳ Kyle G Daniels retweeted
Delgoffe Lab@DelgoffeLab·Nov 12

This trial is of an oncolytic virus that encodes a novel TGFbeta receptor inhibitor that we developed in the lab. Super excited to see it change the lives of cancer patients! See the preclinical paper here: rupress.org/jem/article/220/…

Post attachment
Fyodor Urnov avatar
⟳ Kyle G Daniels retweeted
Fyodor Urnov@UrnovFyodor·Nov 12

Cease doomscrolling and start joyreading: the amazing Cecilia Cotta - with her trademark courage and creativity - leads a team at Tessera to a major advance in the field: generating stable CAR-T cells in vivo using LNP mRNA delivery - a key step towards CAR-T scalability and affordability! Gregor- and Rosalindspeed, Tessera! cell.com/cell/fulltext/S0092…

Talia Ringer 🕊🪬 avatar
⟳ Kyle G Daniels retweeted
Talia Ringer 🕊🪬@TaliaRinger·Nov 9

Check out our upcoming POPL paper "Proof Repair and (Co)algebra Equivalences," which is my favorite paper I've had the pleasure of being a part of. Just finally nails down what proof repair is actually doing. Beautiful work with Trey, Eric, Cosmo, & Alex arxiv.org/abs/2610.36669v1

Polly Fordyce avatar
⟳ Kyle G Daniels retweeted
Polly Fordyce@fordycelab·Nov 7

Let's say you were going to benchmark current algorithms for binder design by quantifying Kds for several libraries of 24,000 VHHs against several targets. Which targets and which algorithms would you nominate and why? What results would you expect?

Jesse Engreitz avatar
⟳ Kyle G Daniels retweeted
Jesse Engreitz@jengreitz·Nov 7

Our latest preprint: • Improved split-pool Perturb-seq method • Gene programs in hiPSC-endothelial differentiation • New role for Hippo pathway in vitro and in vivo • Strategy for improving differentiation by faking cell density biorxiv.org/content/10.64898… 1/

Post attachment
Andrew Scharenberg avatar
⟳ Kyle G Daniels retweeted
Andrew Scharenberg@andyscharenberg·Nov 5

We started Umoja around a fairly simple idea: could we generate CAR T cells directly in a patient, rather than manufacturing those cells outside the body? Our first published in vivo CAR proof-of-concept work in 2022 described the use of our VivoVec delivery platforms to efficiently generate functional CAR T cells in vivo. We subsequently extended that work to show the potential of incorporating our RACR cytokine receptor system to potentiate CAR T cell survival and function. At ASH this year, Umoja will have four presentations spanning three in vivo CAR T cell programs: UB-VV400, UB-VV410 and UB-VV500, including an oral presentation of the first UB-VV400 in vivo RACR/CAR clinical data. Still a lot of work in front of us, but I am very proud of the team that continues to move this science forward. cell.com/molecular-therapy-f… umoja-biopharma.com/news/umo…

Sidi Chen avatar
⟳ Kyle G Daniels retweeted
Sidi Chen@sidichen·Nov 4

11/4/2026 Excited to share our new Nature paper “In vivo CAR-T double knockout screen maps synergistic antitumour gene pairs”. Led by Liqun, with Paul, Kaiyuan, Ariel. Also Tx to support from lab members and Markus, Stephen and Nidhi’s groups. Kudos team! nature.com/articles/s41586-0…

Tino Pleiner avatar
⟳ Kyle G Daniels retweeted
Tino Pleiner@pleinerlab·Nov 2

Membrane protein folding and assembly requires a growing number of ER membrane-bound chaperones. In my lab’s first paper now out @NSMB we show that the EMC forms a supercomplex with the multipass translocon and #ribosome to fold and assemble nascent #calcium channels.@StanfordMed

Post attachment
Jennbrophy.bsky.social avatar
⟳ Kyle G Daniels retweeted
Jennbrophy.bsky.social@jennbrophy7·Oct 31

What drives T-DNA integration? We couldn’t get a convincing answer with existing tools, so we built one! Our new preprint introduces a synthetic biology approach to tracking T-DNA delivery and integration in plants 🌱 biorxiv.org/content/10.64898…

Post attachment
Kyle Concannon, MD avatar
⟳ Kyle G Daniels retweeted
Kyle Concannon, MD@kyleconcannonMD·Oct 31

We can do better than lifelong treatment that prolongs “waiting-to-progress time.” Thrilled to work together toward revolutionary paradigms of cancer treatment with, hopefully, curative potential. Thank you all so much for the opportunity to show our work at @CUCancerCenter!